Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

MDT-AP-2110

Med · Medulloblastoma

26b1eafe-697e-5387-9387-ca78c39f90ea

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
Med
cancer_type_detailed
subtype
Medulloblastoma
cancer_type
Med
subtype
Medulloblastoma
overall_survival_months
18
os_event
true
age_years
2
sex
M
fusion
other ZFTA
new_clusters
C1
umap1_2d
4.192869705
umap2_2d
-0.721550401
umap1_3d
-0.051707545
umap2_3d
-4.031842703
umap3_3d
-0.630195752
dataset
Med-Taylor

GSVA pathway preview (0 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

No GSVA scores available for this sample.

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-2497
medullo-epn-umap@date-based
MedMedulloblastoma0.916
2MDT-AP-2180
medullo-epn-umap@date-based
MedMedulloblastoma0.898
3MNG925
mng-umap@100
0.887
4TCGA-98-A538-01A-11R-A262-07
lung-landscapes@6
cohortSQ10.878
5MDT-AP-3297
medullo-epn-umap@date-based
MedMedulloblastoma0.870
6TCGA-94-7557-01A-11R-2125-07
lung-landscapes@6
cohortMD10.869
71764b9ab-4f37-47c5-8225-40c574433f40
colon-landscapes@1
0.861
8E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9
brain-umap@2
0.861
9MNG753
mng-umap@100
0.857
10MDT-AP-3285
medullo-epn-umap@date-based
MedMedulloblastoma0.856

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.650Inavolisib— uncovered
G2M_CHECKPOINT0.610Inavolisib— uncovered
MYC_TARGETS_V10.570Inavolisib— uncovered
MYC_TARGETS_V20.540Idelalisib— uncovered
DNA_REPAIR0.460Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.450Remibrutinib— uncovered
MTORC1_SIGNALING0.410Inavolisib— uncovered
MITOTIC_SPINDLE0.400Inavolisib— uncovered
TGF_BETA_SIGNALING0.390Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.330Idelalisib— uncovered
FATTY_ACID_METABOLISM0.280Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.270Inavolisib— uncovered
PEROXISOME0.240Idelalisib— uncovered
ADIPOGENESIS0.230Inavolisib— uncovered
ANDROGEN_RESPONSE0.230Inavolisib— uncovered
UV_RESPONSE_UP0.230Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.130Remibrutinib— uncovered
GLYCOLYSIS0.090Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.080Inavolisib— uncovered